Jade Biosciences is developing a pipeline of potentially best-in-class therapies to redefine the standard of care for patients living with autoimmune conditions. Jade is headquartered in Waltham, MA.

Our pipeline of potentially best-in-class biologics was engineered by Paragon Therapeutics, which was founded by leading healthcare investor Fairmount. Jade is the fourth company founded on discovery-stage assets from Paragon, following in the footsteps of Apogee Therapeutics, Spyre Therapeutics, and Oruka Therapeutics.